BTIG raised the firm’s price target on Harrow (HROW) to $63 from $62 and keeps a Buy rating on the shares after its Q2 results and affirmed guidance. The one oddity in the release was a modest decline in VEVYE sales that management explained – the early launch of VEVYE included patients paying nearly full cost for the drug out of pocket and after the start of the VEVYE-4-ALL program, those patients started paying the $59 base price, the analyst tells investors in a research note. The management also discussed the growing sense in the eye-care space that Harrow is an important one-stop player, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow Health: Strong Financial Performance and Product Growth Justify Buy Rating and Raised Price Target
- Harrow price target raised to $64 from $60 at H.C. Wainwright
- Harrow Health Reports Strong Q2 2025 Financial Results
- Harrow Health’s Strong Operational Efficiency and Strategic Partnerships Justify Buy Rating
- HROW Earnings Report this Week: Is It a Buy, Ahead of Earnings?